文献速递心脑血管急症

ACURATE neo2瓣膜与商用经导管心脏瓣膜治疗重度主动脉瓣狭窄的比较(ACURATE IDE):多中心、随机、对照、非劣效性试验

ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial.
PubMed 文献 · Lancet · 2025-05-21
一句话结论在症状性重度主动脉瓣狭窄患者中,ACURATE neo2行TAVR未达到非劣效,1年全因死亡、全部卒中和再住院复合终点显著劣于商用瓣膜。

ACURATE IDE为多中心、随机、对照、非劣效性试验,纳入症状性重度主动脉瓣狭窄且任何外科风险级别的患者,2019年6月10日至2023年4月19日从美国和加拿大71个中心招募1500例,1:1随机分配至ACURATE neo2组(752例)或对照组商用瓣膜SAPIEN 3(SAPIEN 3或SAPIEN 3 Ultra)或Evolut(748例)。主要终点为1年全因死亡、全部卒中和再住院的复合终点,非劣效界值8.0%,采用贝叶斯方法检验。1年时ACURATE neo2组主要复合终点后验中位概率16.2%(95%贝叶斯可信区间13.4-19.1)高于对照组9.5%(7.5-11.9),组间差异6.6%(3.0-10.2),治疗差异上限超过预设非劣效界值8%。1年Kaplan-Meier复合终点发生率ACURATE neo2组14.8%(95%CI 12.5-17.6)vs 对照组9.1%(7.2-11.4),HR 1.71(95%CI 1.26-2.33),p=0.0005。结论认为ACURATE neo2行TAVR未达到非劣效,1年主要复合终点结局显著更差。

要点

  • ACURATE neo2组1年主要复合终点(全因死亡、全部卒中、再住院)后验中位概率16.2% vs 对照组9.5%,组间差异6.6%(95%贝叶斯可信区间3.0-10.2),上限超过非劣效界值8%。
  • 1年Kaplan-Meier复合终点ACURATE neo2组14.8% vs 对照组9.1%,HR 1.71(95%CI 1.26-2.33),p=0.0005。
  • 1年卒中ACURATE neo2组41例 vs 对照组25例,HR 1.68(95%CI 1.02-2.75);全因死亡36例 vs 28例,HR 1.30(95%CI 0.80-2.14)。
  • 1年心血管死亡ACURATE neo2组3.7% vs 对照组1.8%(p=0.024),自发性心肌梗死2.4% vs 0.7%(p=0.0092)。
  • 1年轻度人工瓣膜主动脉瓣反流(中央加瓣周)ACURATE neo2组42.5% vs 对照组24.8%(p<0.0001),中度4.4% vs 1.8%(p=0.0070)。

适用人群与场景

  • 症状性重度主动脉瓣狭窄且任何外科风险级别的患者,来自美国和加拿大71个医疗中心。
  • 随机1:1分配至ACURATE neo2组(752例)或对照组商用瓣膜SAPIEN 3(SAPIEN 3或SAPIEN 3 Ultra)或Evolut(748例)。
  • 所有器械按制造商说明植入。

研究设计与关键结果

  • 多中心、随机、对照、非劣效性试验,纳入1500例症状性重度主动脉瓣狭窄患者,随机分配至ACURATE neo2组(752例)或对照组商用瓣膜(748例),主要终点为1年全因死亡、全部卒中和再住院复合终点,非劣效界值8.0%,采用贝叶斯方法检验。
  • 1年主要复合终点后验中位概率ACURATE neo2组16.2%(95%贝叶斯可信区间13.4-19.1)vs 对照组9.5%(7.5-11.9),组间差异6.6%(3.0-10.2),治疗差异上限超过预设非劣效界值8%,后验概率>0.999。
  • 1年Kaplan-Meier复合终点ACURATE neo2组14.8%(95%CI 12.5-17.6)vs 对照组9.1%(7.2-11.4),HR 1.71(95%CI 1.26-2.33),p=0.0005。
  • 1年全因死亡ACURATE neo2组36/752例 vs 对照组28/748例,HR 1.30(95%CI 0.80-2.14);卒中41例 vs 25例,HR 1.68(95%CI 1.02-2.75);再住院38例 vs 25例,HR 1.57(95%CI 0.95-2.61)。
  • 1年心血管死亡ACURATE neo2组3.7% vs 对照组1.8%(p=0.024),自发性心肌梗死2.4% vs 0.7%(p=0.0092)。
  • 1年人工瓣膜主动脉瓣反流(中央加瓣周)ACURATE neo2组轻度42.5% vs 对照组24.8%(p<0.0001),中度4.4% vs 1.8%(p=0.0070),重度0.5% vs 0%(p=0.12)。

证据类型、等级与局限

  • 证据类型:多中心、随机、对照、非劣效性试验。
  • 非劣效界值8.0%,采用贝叶斯方法检验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在症状性重度主动脉瓣狭窄患者中,ACURATE neo2行TAVR未达到非劣效,1年全因死亡、全部卒中和再住院复合终点结局显著更差(原文结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: ACURATE neo2 is an open-cell, supra-annular, self-expanding transcatheter heart valve that is commercially available in over 50 countries but has not previously been evaluated in a randomised trial. ACURATE-IDE aimed to prospectively evaluate the safety and efficacy of transcatheter aortic valve replacement (TAVR) with the ACURATE neo2 valve compared with commercially available valves for the treatment of severe symptomatic aortic stenosis.

METHODS: In this multicentre, randomised, controlled, non-inferiority trial, patients with symptomatic severe aortic stenosis and any level of surgical risk were recruited from 71 medical centres in the USA and Canada. Eligible patients were randomly assigned (1:1) to TAVR with ACURATE neo2 or one of the control valves, SAPIEN 3 (SAPIEN 3 or SAPIEN 3 Ultra) or Evolut, using permuted block randomisation with a pseudo-random number generator, and stratified by the clinical investigation site and type of control valve. All devices were implanted according to the manufacturer's instructions. The primary endpoint was a composite of all-cause mortality, all stroke, and rehospitalisation at 1 year, tested for non-inferiority using a Bayesian approach. The primary analysis was performed in the intention-to-treat population and sensitivity analyses were done in the implanted population. The non-inferiority margin was 8·0%. This study is registered with ClinicalTrials.gov, NCT03735667, and is ongoing.

FINDINGS: Between June 10, 2019, and April 19, 2023, 1500 patients were recruited, of whom 752 were randomly assigned to the ACURATE neo2 group and 748 to the control group. The median age of participants was 79 years (IQR 74-83). 778 (51·9%) of 1500 patients were female and 721 (48·1%) were male. At 1 year, the posterior median probability of the primary composite endpoint was higher in the ACURATE neo2 group (16·2% [95% Bayesian credible interval 13·4-19·1) than in the control group (9·5% [7·5-11·9]; between-group difference 6·6% [3·0-10·2]). The upper bound of treatment difference exceeded the prespecified non-inferiority margin of 8%, with a posterior probability of treatment difference of >0·999. At 1 year, the ACURATE neo2 group, had significantly higher Kaplan-Meier rates of the composite endpoint of all-cause mortality, all stroke, and rehospitalisation (14·8% [95% CI 12·5-17·6] vs 9·1% [7·2-11·4]; hazard ratio [HR] 1·71 [95% CI 1·26-2·33]; p=0·0005). At 1 year, all-cause mortality occurred in 36 of 752 patients in the ACURATE neo2 group versus 28 of 748 patients in the control group (HR 1·30 [95% CI 0·80-2·14]), stroke in 41 patients versus 25 patients (1·68 [1·02-2·75]), and rehospitalisation in 38 patients versus 25 patients (1·57 [0·95-2·61]). Cardiovascular mortality (3·7% vs 1·8%, p=0·024) and spontaneous myocardial infarction at 1 year (2·4% vs 0·7%, p=0·0092) were more frequent in the ACURATE neo2 group than in the control group. Prosthetic valve aortic regurgitation (central plus paravalvular) at 1 year was significantly more frequent in the ACURATE neo2 group than in the control group (mild aortic regurgitation 42·5% vs 24·8%, p<0·0001; moderate 4·4% vs 1·8%, p=0·0070; severe 0·5% vs 0%; p=0·12).

INTERPRETATION: In patients with symptomatic severe aortic stenosis, TAVR with ACURATE neo2 did not meet non-inferiority and resulted in significantly worse outcomes with respect to the primary endpoint of composite of all-cause mortality, all stroke, and rehospitalisation at 1 year when compared with commercial valves.

FUNDING: Boston Scientific.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Makkar RR, Ramana RK, Gnall E, et al. ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial. Lancet. 2025. PMID: 40412426. doi:10.1016/S0140-6736(25)00319-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。